BACKGROUND: In areas where malaria is endemic, infants aged <3 months appear to be relatively protected from symptomatic and severe Plasmodium falciparum malaria, but less is known about the effect of Plasmodium vivax infection in this age group. METHODS: To define malaria morbidity in the first year of life in an area where both multidrug-resistant P. falciparum and P. vivax are highly prevalent, data were gathered on all infants attending a referral hospital in Papua, Indonesia, using systematic data forms and hospital computerized records. Additional clinical and laboratory data were prospectively collected from inpatients aged <3 months. RESULTS: From April 2004 through April 2008, 4976 infants were admitted to the hospital, of whom 1560 (31%) had malaria, with infection equally attributable to P. falciparum and P. vivax. The case-fatality rate was similar for inpatients with P. falciparum malaria (13 [2.2%] of 599 inpatients died) and P. vivax malaria (6 [1.0%] of 603 died; P= .161), whereas severe malarial anemia was more prevalent among those with P. vivax malaria (193 [32%] of 605 vs. 144 [24%] of 601; P= .025). Of the 187 infants aged <3 months, 102 (56%) had P. vivax malaria, and 55 (30%) had P. falciparum malaria. In these young infants, infection with P. vivax was associated with a greater risk of severe anemia (odds ratio, 2.4; 95% confidence interval, 1.03-5.91; P= .041) and severe thrombocytopenia (odds ratio, 3.3; 95% confidence interval, 1.07-10.6; P= .036) compared with those who have P. falciparum infection. CONCLUSIONS: P. vivax malaria is a major cause of morbidity in early infancy. Preventive strategies, early diagnosis, and prompt treatment should be initiated in the perinatal period.
BACKGROUND: In areas where malaria is endemic, infants aged <3 months appear to be relatively protected from symptomatic and severe Plasmodium falciparummalaria, but less is known about the effect of Plasmodium vivaxinfection in this age group. METHODS: To define malaria morbidity in the first year of life in an area where both multidrug-resistant P. falciparum and P. vivax are highly prevalent, data were gathered on all infants attending a referral hospital in Papua, Indonesia, using systematic data forms and hospital computerized records. Additional clinical and laboratory data were prospectively collected from inpatients aged <3 months. RESULTS: From April 2004 through April 2008, 4976 infants were admitted to the hospital, of whom 1560 (31%) had malaria, with infection equally attributable to P. falciparum and P. vivax. The case-fatality rate was similar for inpatients with P. falciparum malaria (13 [2.2%] of 599 inpatients died) and P. vivax malaria (6 [1.0%] of 603 died; P= .161), whereas severe malarial anemia was more prevalent among those with P. vivax malaria (193 [32%] of 605 vs. 144 [24%] of 601; P= .025). Of the 187 infants aged <3 months, 102 (56%) had P. vivax malaria, and 55 (30%) had P. falciparum malaria. In these young infants, infection with P. vivax was associated with a greater risk of severe anemia (odds ratio, 2.4; 95% confidence interval, 1.03-5.91; P= .041) and severe thrombocytopenia (odds ratio, 3.3; 95% confidence interval, 1.07-10.6; P= .036) compared with those who have P. falciparum infection. CONCLUSIONS: P. vivax malaria is a major cause of morbidity in early infancy. Preventive strategies, early diagnosis, and prompt treatment should be initiated in the perinatal period.
Authors: R W Snow; J A Omumbo; B Lowe; C S Molyneux; J O Obiero; A Palmer; M W Weber; M Pinder; B Nahlen; C Obonyo; C Newbold; S Gupta; K Marsh Journal: Lancet Date: 1997-06-07 Impact factor: 79.321
Authors: B M Afolabi; L A Salako; A G Mafe; U B Ovwigho; K A Rabiu; N O Sanyaolu; M M Ibrahim Journal: Am J Trop Med Hyg Date: 2001-12 Impact factor: 2.345
Authors: L Slutsker; C O Khoromana; A W Hightower; A Macheso; J J Wirima; J G Breman; D L Heymann; R W Steketee Journal: Am J Trop Med Hyg Date: 1996 Impact factor: 2.345
Authors: Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey Journal: Am J Trop Med Hyg Date: 2007-12 Impact factor: 2.345
Authors: Tonia Woodberry; Gabriela Minigo; Kim A Piera; Jennifer C Hanley; Harini D de Silva; Ervi Salwati; Enny Kenangalem; Emiliana Tjitra; Ross L Coppel; Ric N Price; Nicholas M Anstey; Magdalena Plebanski Journal: J Infect Dis Date: 2008-07-01 Impact factor: 5.226
Authors: Muhammad Karyana; Lenny Burdarm; Shunmay Yeung; Enny Kenangalem; Noah Wariker; Rilia Maristela; Ketut Gde Umana; Ram Vemuri; Maurits J Okoseray; Pasi M Penttinen; Peter Ebsworth; Paulus Sugiarto; Nicholas M Anstey; Emiliana Tjitra; Richard N Price Journal: Malar J Date: 2008-08-02 Impact factor: 2.979
Authors: Jeanne R Poespoprodjo; Afdal Hasanuddin; Wendelina Fobia; Paulus Sugiarto; Enny Kenangalem; Daniel A Lampah; Emiliana Tjitra; Ric N Price; Nicholas M Anstey Journal: Am J Trop Med Hyg Date: 2010-04 Impact factor: 2.345
Authors: Suryadi N N Tatura; Elizabeth Clarissa Wowor; Jose M Mandei; Rocky Wilar; Sarah M Warouw; Johnny Rompis; Priscilla Kalensang; Joseph Tuda Journal: Am J Trop Med Hyg Date: 2018-01-04 Impact factor: 2.345
Authors: Antonio M Quispe; Edwar Pozo; Edith Guerrero; Salomón Durand; G Christian Baldeviano; Kimberly A Edgel; Paul C F Graf; Andres G Lescano Journal: Am J Trop Med Hyg Date: 2014-04-21 Impact factor: 2.345
Authors: Thiago Castro-Gomes; Luiza C Mourão; Gisely C Melo; Wuelton M Monteiro; Marcus V G Lacerda; Érika M Braga Journal: Infect Immun Date: 2014-08-04 Impact factor: 3.441